Summit Therapeutics plc : Miscellaneous

Summit Therapeutics plc
("Summit" or the "Company")

SUMMIT APPOINTS PANMURE GORDON AS JOINT BROKER

Oxford, UK, 16 November 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces the appointment of Panmure Gordon as joint broker with immediate effect to act alongside N+1 Singer.

About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

Contacts

Summit Glyn Edwards / Richard Pye (UK office) Erik Ostrowski / Michelle Avery (US office)	Tel: +44 (0)1235 443 951   +1 617 225 4455
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson	Tel: +44 (0)20 7213 0880
N+1 Singer (Joint Broker) Aubrey Powell / Jen Boorer	Tel: +44 (0)20 7496 3000
Pamure Gordon (Joint Broker) Freddy Crossley / Duncan Monteith, Corporate Finance Tom Salvesen, Corporate Broking	Tel: +44 (0)20 7886 2500
MacDougall Biomedical Communications (US) Karen Sharma	Tel: +1 781 235 3060 ksharma@macbiocom.com
Consilium Strategic Communications (UK) Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Philippa Gardner	Tel: +44 (0)20 3709 5700 summit@consilium-comms.com

-END-

---